{"id":"NCT01546649","sponsor":"Takeda","briefTitle":"A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2012-03-07","resultsPosted":"2015-11-26","lastUpdate":"2015-11-26"},"enrollment":167,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Premenopausal Breast Cancer"],"interventions":[{"type":"DRUG","name":"TAP-144-SR(6M)","otherNames":[]},{"type":"DRUG","name":"TAP-144-SR(3M)","otherNames":[]}],"arms":[{"label":"TAP-144-SR(6M)","type":"EXPERIMENTAL"},{"label":"TAP-144-SR(3M)","type":"ACTIVE_COMPARATOR"}],"summary":"Hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) will be evaluated against TAP-144-SR(3M) in postoperative and hormone therapy-naïve patients with premenopausal breast cancer","primaryOutcome":{"measure":"Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=<30 pg/mL) From Week 4 Through Week 48","timeFrame":"Week 4 up to Week 48","effectByArm":[{"arm":"TAP-144-SR (6M)","deltaMin":97.6,"sd":null},{"arm":"TAP-144-SR (3M)","deltaMin":96.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":15,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":83},"commonTop":["Hot flush","Nasopharyngitis","Radiation skin injury","Injection site induration","Injection site pain"]}}